These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 25103655)

  • 41. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
    Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy.
    Sarraf D; Chan C; Rahimy E; Abraham P
    Retina; 2013 Sep; 33(8):1551-7. PubMed ID: 23652578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results.
    Kanesa-Thasan A; Grewal DS; Gill MK; Lyon AT; Mirza RG
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):638-41. PubMed ID: 26114844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration.
    Rouvas A; Chatziralli I; Androu A; Mpougatsou P; Alonistiotis D; Douvali M; Kabanarou SA; Theodossiadis P
    Int Ophthalmol; 2019 Feb; 39(2):431-440. PubMed ID: 29404860
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
    Berg K; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results.
    Chevreaud O; Oubraham H; Cohen SY; Jung C; Blanco-Garavito R; Gherdaoui F; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):743-751. PubMed ID: 27913869
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of retinal pigment epithelial tear in serous vascularized pigment epithelium detachment.
    Clemens CR; Bastian N; Alten F; Milojcic C; Heiduschka P; Eter N
    Acta Ophthalmol; 2014 Feb; 92(1):e50-6. PubMed ID: 23819839
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration.
    Mariani A; Deli A; Ambresin A; Mantel I
    Graefes Arch Clin Exp Ophthalmol; 2011 Nov; 249(11):1635-42. PubMed ID: 21725716
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
    Wykoff CC; Brown DM; Maldonado ME; Croft DE
    Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
    Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
    Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRIDGE ARCH-SHAPED SEROUS RETINAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION.
    Fajnkuchen F; Cohen SY; Thay N; Ayrault S; Delahaye-Mazza C; Grenet T; Nghiem-Buffet S; Quentel G; Giocanti-Auregan A
    Retina; 2016 Mar; 36(3):476-82. PubMed ID: 26355948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis.
    Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
    Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS; Daftari I; Phillips T; Morse LS
    Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration.
    Krebs I; Vécsei Marlovits V; Bodenstorfer J; Glittenberg C; Ansari Shahrezaei S; Ristl R; Binder S
    Acta Ophthalmol; 2013 May; 91(3):e178-83. PubMed ID: 23241227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Volumetric Analysis of Vascularized Serous Pigment Epithelial Detachment Progression in Neovascular Age-Related Macular Degeneration Using Optical Coherence Tomography Angiography.
    Au A; Hou K; Dávila JP; Gunnemann F; Fragiotta S; Arya M; Sacconi R; Pauleikhoff D; Querques G; Waheed N; Freund KB; Sadda S; Sarraf D
    Invest Ophthalmol Vis Sci; 2019 Aug; 60(10):3310-3319. PubMed ID: 31369033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retinal pigment epithelial tears following ranibizumab therapy for fibrovascular retinal pigment epithelial detachment due to occult age-related macular degeneration.
    Figurska M
    Med Sci Monit; 2012 Jan; 18(1):CR32-38. PubMed ID: 22207117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections.
    Chan CK; Abraham P; Meyer CH; Kokame GT; Kaiser PK; Rauser ME; Gross JG; Nuthi AS; Lin SG; Daher NS
    Retina; 2010 Feb; 30(2):203-11. PubMed ID: 19952998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab.
    Calvo P; Ferreras A; Al Adel F; Wang Y; Brent MH
    Br J Ophthalmol; 2015 Jun; 99(6):723-6. PubMed ID: 25425713
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anatomical and visual outcomes of ranibizumab injections in retinal pigment epithelium tears.
    Erol MK; Ozdemir O; Coban DT; Ceran BB; Sari ES
    Arq Bras Oftalmol; 2015; 78(3):168-72. PubMed ID: 26222106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.